ECOG-PS (≥2 vs. 0/1) |
1.13 |
0.79–1.61 |
0.52 |
BMI (< 18.5 vs. ≥ 18.5) |
1.78 |
1.28–2.50 |
<
0.001* |
Number of organs involved as metastatic lesions (≥ 2 vs. 0/1) |
1.22 |
0.89–1.68 |
0.21 |
EGFR mutation status (Exon 21 L858R vs. Exon 19 del) |
1.05 |
0.77–1.43 |
0.78 |
EGFR mutation status (Other vs. Exon 19 del) |
2.59 |
1.51–4.45 |
< 0.001* |
GRIm score (High vs. Low) |
1.94 |
1.27–2.97 |
0.0023* |
Concomitant medications (≥5 vs. ≤ 4) |
1.34 |
0.99–1.82 |
0.056 |
Variants for OS |
HR |
95% CI |
P |
Age group (≥ 75 vs. 65-74) |
1.57 |
1.12–2.21 |
0.017* |
ECOG-PS (≥2 vs. 0/1) |
1.54 |
1.06–2.25 |
0.024* |
BMI (< 18.5 vs. ≥ 18.5) |
1.86 |
1.29–2.67 |
<
0.001* |
Number of organs involved as metastatic lesions (≥ 2 vs. 0/1) |
1.60 |
1.13–2.26 |
0.0079* |
EGFR mutation status (Exon 21 L858R vs. Exon 19 del) |
1.13 |
0.79–1.60 |
0.50 |
EGFR mutation status (Other vs. Exon 19 del) |
1.91 |
1.08–3.39 |
0.026* |
Osimertinib use in clinical course (Yes vs. No) |
0.44 |
0.27–0.71 |
< 0.001* |
GRIm score (High vs. Low) |
2.37 |
1.53–3.67 |
<
0.001* |
Concomitant medications (≥5 vs. ≤ 4) |
1.58 |
1.13–2.21 |
0.0076* |